Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
- Study ID
- NCT07677072
- Status
- Recruiting
Conditions
- Fragility Fractures
- Frailty
- Osteoporosis
- Postmenopausal Osteoporosis
Eligibility Criteria
- Sex
- FEMALE
- Age
- 45 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.
Key Dates
- Start date
- May 15, 2026
- Status verified
- Jun 2026
- Primary completion
- Dec 1, 2026
- Completion
- Dec 1, 2026
Study Design
- Enrollment
- 98 participants (estimated)
Arms
- Arm: Postmenopausal Women Undergoing Osteoporosis EvaluationPostmenopausal women undergoing routine osteoporosis assessment will be included in this observational cohort. Participants will undergo bone mineral density measurement, routine osteoporosis laboratory evaluation, FRAX assessment, handgrip strength measurement, and serum lumican analysis. No treatment or interventional procedure will be administered as part of the study.
Primary Outcome Measure
Serum Lumican Level and Bone Mineral Density Association [ Time Frame: Baseline (at study enrollment) ]
Central Contacts
- Dilek Ün Oğuzhanasiltürk, MD+90 5056367184
Related Studies
- Safety, Efficacy of FFP From Healthy Donors to Ameliorate Frailty and Enhance Immune Function in Older IndividualsPHASE1/PHASE2 · Enrolling By Invitation · Dipnarine Maharaj · Boynton Beach, Florida
- Identifying Modifiable PAtient Centered Therapeutics (IMPACT) FrailtyRecruiting · University of California, Los Angeles · Los Angeles, California
- Meal Delivery and ExerciseRecruiting · The University of Texas Health Science Center, Houston · Houston, Texas
- Mode of Exercise and Bone Biomarkers in Older VeteransRecruiting · VA Office of Research and Development · Aurora, Colorado